A Toronto AI-Cardiac Diagnostics Company Just Cleared Three of the Hardest Validation Bars in Medtech

Stock Information for Destination XL Group Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Destination XL Group Inc.

Ventripoint Announces Adoption of Semi-Annual Reporting (SAR)
Ventripoint Provides Videoconference Link to Annual General Meeting and Corporate Update
Ventripoint Announces Closing of $308,030 Non-Brokered Units Private Placement
Cardiac AI Diagnostics Stack Validation Wins Across Regulatory and Commercial Fronts
Ventripoint Issues Shares for Payment of Debenture Interest
The $59B Quiet Shift Reshaping How Patients Access Care
Wall Street's Cardiac Bet: Where Diagnostics Meet the Money
Ventripoint to Exhibit at the 59th Annual Meeting of the Association for European Paediatric and Congenital Cardiology

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.